Hwaseong, South Korea

Sang Youn Hwang

This inventor holds 6 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 7 EPO patents. Top assignee: Hanmi Pharm. Co., Ltd.. Active years: 2017-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sang Youn Hwang. Retrieved from https://idiyas.com/inventor/sang-youn-hwang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 5.8

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Hwaseong-si, KR (2017 - 2019)
  • Gyeonggi-do, KR (2019)

Company Filing History:


Years Active: 2017-2019

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovations of Sang Youn Hwang

Introduction

Sang Youn Hwang is a notable inventor based in Hwaseong-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for metabolic diseases. With a total of six patents to his name, Hwang's work focuses on improving patient outcomes through innovative drug formulations.

Latest Patents

One of Hwang's latest patents is titled "Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease." This invention relates to a pharmaceutical composition designed to prevent or treat non-alcoholic fatty liver disease. The composition includes a long-acting GLP-1/glucagon receptor dual agonist, which not only minimizes the side effects commonly associated with conventional treatments, such as weight gain, but also enhances patient convenience by reducing the frequency of administration. Additionally, this dual agonist improves in vivo sustainability and stability.

Another significant patent by Hwang is "Long-acting insulin and use thereof." This invention involves an insulin analog that has a reduced binding affinity for insulin receptors, aimed at increasing the blood half-life of insulin. The patent also covers a conjugate and a method for preparing long-acting insulin, which could potentially revolutionize diabetes management.

Career Highlights

Hwang has worked with prominent companies in the pharmaceutical industry, including Hanmi Pharmaceutical Co., Ltd. and Hanmi Science Co., Ltd. His experience in these organizations has allowed him to contribute to groundbreaking research and development in drug formulation and delivery.

Collaborations

Throughout his career, Hwang has collaborated with talented individuals such as Sung Youb Jung and Se Chang Kwon. These partnerships have fostered innovation and have been instrumental in advancing his research projects.

Conclusion

Sang Youn Hwang's contributions to the field of pharmaceuticals, particularly in the development of innovative treatments for metabolic diseases, highlight his role as a leading inventor. His patents reflect a commitment to improving patient care and advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…